# PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP

> **NCT02401061** · PHASE1,PHASE2 · TERMINATED · sponsor: **Protalex, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** PRTX-100

## Key facts

- **NCT ID:** NCT02401061
- **Lead sponsor:** Protalex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09
- **Primary completion:** 2019-03
- **Final completion:** 2019-06-04
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Enough data has been collected to allow analysis of safety profile and risk-benefit.
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02401061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02401061, "PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02401061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*